Cargando…

Enhanced thromboprophylaxis in critically ill patients with COVID-19 infection

BACKGROUND: Patients with severe SARS-CoV-2 infection have been shown to have abnormal coagulation parameters and are at increased risk of thromboembolism. The optimal thromboprophylaxis regimen that minimizes thrombosis without increased risk of serious bleeding is uncertain. OBJECTIVES: To describ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kummer, R.L., Considine, K.A., Rankin, M.A., Hubbard, L.M., Lam, T.S., Thornton, L.T., Lindsay, A.R., Ahiskali, A.S., Leatherman, J.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019488/ http://dx.doi.org/10.1016/j.tru.2021.100048

Ejemplares similares

Adequate thromboprophylaxis in critically ill patients
por: Levi, Marcel
Publicado: (2010)

Renal function and thromboprophylaxis in critically ill patients
por: Scholey, Gareth M, et al.
Publicado: (2010)

Thromboprophylaxis in Critically Ill Coronavirus Disease 2019 Patients
por: Piagnerelli, Michaël, et al.
Publicado: (2020)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
por: Jonmarker, Sandra, et al.
Publicado: (2020)

Intensified thromboprophylaxis in COVID-19 critically ill patients: Is it enough?
por: de Montmollin, Etienne, et al.
Publicado: (2021)

Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
por: Bachler, Mirjam, et al.
Publicado: (2022)

Thromboprophylaxis in critical care
por: Helms, Julie, et al.
Publicado: (2022)

Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
por: Lauzier, François, et al.
Publicado: (2014)

High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
por: Hamada, S. R., et al.
Publicado: (2017)

COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
por: Ferrandis, Raquel, et al.
Publicado: (2020)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
por: Li, Guowei, et al.
Publicado: (2016)

Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study
por: Ferrandis, R., et al.
Publicado: (2023)

What Do We Know about Thromboprophylaxis and Its Monitoring in Critically Ill Patients?
por: Cauchie, Philippe, et al.
Publicado: (2021)

A comparison of three thromboprophylaxis regimens in critically ill COVID-19 patients: An analysis of real-world data
por: Alrashed, Ahmed, et al.
Publicado: (2022)

Pharmacological and Mechanical Thromboprophylaxis in Critically Ill Patients: a Network Meta-Analysis of 12 Trials
por: Park, Jonghanne, et al.
Publicado: (2016)

Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection
por: Fattorutto, Maurizio, et al.
Publicado: (2021)

New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients
por: MacDougall, Kira, et al.
Publicado: (2020)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis
por: Hafiz, Awatif, et al.
Publicado: (2023)

Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older
por: Ageno, Walter, et al.
Publicado: (2021)

Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial
por: Pai, Menaka, et al.
Publicado: (2018)

Systemic Corticosteroids And Transition To Delirium in Critically Ill Patients
por: Wolters, AE, et al.
Publicado: (2015)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial
por: Alavi-Darazam, Ilad, et al.
Publicado: (2022)

Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
por: Sahle, Berhe W., et al.
Publicado: (2023)

Venous Thromboprophylaxis in Spine Surgery
por: Alvarado, Anthony M., et al.
Publicado: (2019)

Thromboprophylaxis strategies for COVID-19 patients
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients
por: Cuker, Adam, et al.
Publicado: (2022)

Outcomes following pancreatic surgery using three different thromboprophylaxis regimens
por: Hanna‐Sawires, R. G., et al.
Publicado: (2019)

Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
por: Cook, Deborah, et al.
Publicado: (2008)

A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
por: Robinson, Sian, et al.
Publicado: (2013)

Prevalence of Low Limb Venous Thromboembolic Events in Mild and Severe/Critically Ill Patients with COVID-19 Despite Pharmacological Thromboprophylaxis
por: Zhang, Cong, et al.
Publicado: (2020)

Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
por: Cohen, Alexander T
Publicado: (2018)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
por: Raskob, Gary E., et al.
Publicado: (2022)

Metabolic acidosis and organ dysfunctions in critically ill patients
por: Taniguchi, LU, et al.
Publicado: (2003)

P.0811 Factors and outcomes associated with delirium in critically ill COVID-19 patients
por: Martins, S., et al.
Publicado: (2021)

Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care
por: Willems, R. A. L., et al.
Publicado: (2023)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
por: Spyropoulos, Alex C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b6189nte24r6jipev82ii2ca9p